Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

Clascoterone cream 1% plus adapalene gel 0.3% offers an effective, well-tolerated topical option for moderate to severe acne, ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. In a clinical trial, scientists are investigating whether a vaccine could treat patients with ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and ...

USA: Researchers have found in a new study that Clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% (CAB) ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Medically reviewed by Casey Gallagher, MD Neck acne happens when oil, sweat, dead skin cells, or products clog your ...

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...